The right diagnosis,
right away,
at the right price.

We are the creators of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. We have just obtained our CE-IVD Mark for the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX) which detects viruses and bacteria causing respiratory tract infections, the only solution of this kind in Europe. See more >>

News

2025.02.12

Genomtec to issue shares to raise funds to support commercialization of projects

The company’s shareholder – 5HT FR intends to sell 1.3 million existing shares of the company in a public offering and use the entire amount of the funds raised to acquire shares of the new issue. Genomtec S.A. has called an Extraordinary General Meeting on March 12, 2025, at which the company’s shareholders will vote […]

2025.01.28

Genomtec has filed a second patent application for the OncoSNAAT oncology project

Genomtec SA announced today that it has filed a patent application with the British Patent Office for an innovative technology for the diagnosis of single-nucleotide genetic changes. The Company’s strategy includes extending patent protection under the international PCT procedure. “The OncoSNAAT project is progressing according to schedule, bringing us closer to creating an innovative diagnostic […]

2024.06.25

Webinar: Trends in the M&A Market Specific to In-Vitro Diagnostics | 27 June, 2024, 3:00 p.m. (CEST)

Dear Investors GENOMTEC S.A. invite you to an investor webinar discussing the market in which the company operates and trends in the M&A market specific to in-vitro diagnostics, presented by the company’s partner, Clairfield. The meeting will be conducted in English. Representatives from Clairfield Partners: Edward Grey – Managing Director Peter Chudy – Partner from […]

Awards